Dermatology ·
Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence

Listen to this post
read by AI voices · all episodesTHE SHORT READ
Veradermics reported company topline 12-month results from its phase 2/3 Study 302 of VDPHL01, an extended-release oral minoxidil, in 519 men with pattern hair loss.
A Quebec cohort study in JAMA Dermatology found higher than expected cancer incidence in patients with morphea and with systemic sclerosis.
THE DETAILS
- Research Nov 9, 2026Veradermics reported company topline 12-month results from Study 302, a phase 2/3 trial that randomized 519 men with mild-to-moderate pattern hair loss to VDPHL01 8.5 mg once or twice daily or placebo, with placebo patients crossed over to the drug after month 6. Non-vellus hair count rose 43.9 hairs/cm² with twice-daily and 29.7 hairs/cm² with once-daily dosing from baseline to month 12, the company said. Placebo-controlled month-6 results were reported in April, according to Healio. The company reported no treatment-related serious adverse events. VDPHL01 is not FDA approved.
- Research Nov 11, 2026In linked administrative health databases from Quebec, Canada, covering 1996 to 2019, overall cancer incidence was increased in 6,181 patients with morphea (standardized incidence ratio 1.24, 95% CI 1.14 to 1.35) and 8,133 with systemic sclerosis (1.37, 95% CI 1.27 to 1.48), according to the study published Nov. 11 in JAMA Dermatology. Hematologic cancer risk was elevated in systemic sclerosis (standardized incidence ratio 2.40, 95% CI 1.92 to 2.96). Immunosuppressant use was associated with lower cancer risk in both groups.Sources: JAMA Dermatology, PubMed
The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties